Profile data is unavailable for this security.
About the company
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
- Revenue in USD (TTM)0.00
- Net income in USD-29.16m
- Incorporated2005
- Employees88.00
- LocationXBiotech Inc5217 WINNEBAGO LANEAUSTIN 78744United StatesUSA
- Phone+1 (512) 386-2900
- Websitehttps://www.xbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -115.01m | 66.19m | 152.00 | -- | 0.3294 | -- | -- | -20.22 | -20.22 | 0.00 | 20.98 | 0.00 | -- | -- | 0.00 | -59.52 | -36.24 | -66.08 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.0088 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 69.62m | 23.00 | -- | 11.02 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Coeptis Therapeutics Holdings Inc | 500.99k | -11.28m | 69.78m | 5.00 | -- | 6.03 | -- | 139.29 | -3.47 | -3.47 | 0.1476 | 2.01 | 0.0433 | -- | 11.65 | 100,198.00 | -118.13 | -42.24 | -167.86 | -44.32 | 72.96 | -- | -2,727.81 | -- | -- | -73.66 | 0.0224 | -- | -- | -- | 53.85 | -- | -- | -- |
| Spruce Biosciences Inc | 697.00k | -47.88m | 70.95m | 9.00 | -- | 6.94 | -- | 101.80 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 71.10m | 13.00 | -- | 1,587.38 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Medicinova Inc | 257.92k | -12.01m | 72.74m | 13.00 | -- | 1.65 | -- | 282.01 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| XBiotech Inc | 0.00 | -29.16m | 74.69m | 88.00 | -- | 0.4471 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 76.62m | 103.00 | 14.38 | 1.70 | 7.93 | 218.30 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| Ibio Inc | 500.00k | -20.11m | 76.69m | 20.00 | -- | 0.8024 | -- | 153.37 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 77.25m | -- | -- | -- | -- | 29.58 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| ImageneBio Inc | 0.00 | -46.14m | 77.27m | 15.00 | -- | 0.5526 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 78.98m | 4.00 | -- | 0.7767 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 80.76m | 19.00 | -- | 4.13 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 80.94m | 44.00 | -- | 1.17 | -- | 28.70 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 84.43m | 213.00 | 36.48 | 20.25 | 21.23 | 1.45 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
Data as of Feb 13 2026. Currency figures normalised to XBiotech Inc's reporting currency: US Dollar USD
5.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 30 Sep 2025 | 416.34k | 1.37% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 254.46k | 0.84% |
| Geode Capital Management LLCas of 31 Dec 2025 | 221.12k | 0.73% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 200.97k | 0.66% |
| RBF Capital LLCas of 30 Sep 2025 | 200.00k | 0.66% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 162.50k | 0.53% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 91.58k | 0.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 73.01k | 0.24% |
| Jane Street Capital LLCas of 31 Dec 2025 | 69.74k | 0.23% |
| Squarepoint OPS LLCas of 31 Dec 2025 | 64.00k | 0.21% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
